Prescription Drug Cost Provisions of the Inflation Reduction Act
15m
·
JAMA Health Forum Editors' Summary
·
President Biden has signed into law the Inflation Reduction Act containing important provisions related to prescription drug costs. JAMA Health Forum Editor John Z. Ayanian, MD, MPP, and Deputy Editor Melinda B. Buntin, PhD, discuss the effects of these provisions on patients with Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women’s Hospital.
Related Content:
- New Reforms to Prescription Drug Pricing in the US
- Estimating Rebates and Other Discounts Received by Medicare Part D
- Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018
- Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
- Improving Prescription Drug Affordability Through Regulatory Action
The episode Prescription Drug Cost Provisions of the Inflation Reduction Act from the podcast JAMA Health Forum Editors' Summary has a duration of
15:33. It was first published
More episodes from JAMA Health Forum Editors' Summary
Differences in Services Provided at Public and Nonprofit Hospitals Related to the 340B Drug Discount Program
JAMA Health Forum Editor John Ayanian, MD, MPP, speaks with Kelsey M. Owsley, PhD, of the University of Arkansas, and Sayeh Nikay, PhD, MPH, of the University of Minnesota, about how the 340B drug discount program influences the services offered by public and nonprofit hospitals. They also discuss new state policies and proposed federal policies to promote greater transparency and accountability in the 340B program.
Related Content:
- US Hospital Service Availability and New 340B Program Participation
- Public Hospitals May Use the 340B Program Differently Than Nonprofit Hospitals
Measuring Medicaid Enrollment More Accurately to Guide Post–COVID-19 Pandemic Policy
Benjamin D. Sommers, MD, PhD, of Harvard University, speaks with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, about differences in Medicaid enrollment as measured in surveys and administrative data. These differences have implications for estimating coverage now that the federal policy of continuous Medicaid eligibility during the COVID-19 pandemic has ended.
Related Content:
- Survey-Reported Coverage in 2019-2022 and Implications for Unwinding Medicaid Continuous Eligibility
Comparing Home Health Services in Traditional Medicare and Medicare Advantage
JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, speak with Rachel A. Prusynski, DPT, PhD, of the University of Washington about differences in the use and outcomes of home health services provided to beneficiaries in traditional Medicare and Medicare Advantage.
Related Content:
- Differences in Home Health Services and Outcomes Between Traditional Medicare and Medicare Advantage
Changes in Access to Care and Preventive Services by Race and Ethnicity During the COVID-19 Pandemic
The COVID-19 pandemic has caused major disruptions in ambulatory care. In this interview with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses how access to care and preventive services changed for different racial and ethnic groups in the US from 2019 to 2022.
Related Content:
- Changes in Health Care Access and Preventive Health Screenings by Race and Ethnicity
Opioid Prescription Duration Limits
JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, speak with Lindsay D. Allen, PhD, about how setting-specific opioid prescription duration limits helped reduce opioid overuse in West Virginia.
Related Content:
- Opioid Prescribing Patterns After Imposition of Setting-Specific Limits on Prescription Duration